US.BDX · Becton Dickinson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.0031256405001026,
        "turnoverUsdM": 339.651585,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.BDX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 187.3414,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.8,
      "stop_loss_percent": 4,
      "take_profit_price": 209.2074,
      "target_multiplier": 2.2,
      "technical_strength": 2.45,
      "take_profit_percent": 7.2
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.7971913130227917,
    "stopLossPercent": 4.006251281000205,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 77.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 70.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 188.8975,
    "ma50": 186.178,
    "close": 195.16,
    "prevClose": 195.03,
    "avgVolume20": 1494084,
    "volumeRatio": 1.16,
    "changePercent": 0.07
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.00421940928270037,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 1.1625790333301047,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 0.7596790925001299,
      "volat_points": 0,
      "day_range_pct": 0.015781922525107524,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 77.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.9,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 58,
        "contribution": 2.9
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 12,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 80,
        "contribution": 12
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 21.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72.33,
        "contribution": 21.7
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "謹慎買入",
    "result": 70.4,
    "details": [
      "基本面分析總分: 2.9/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 12/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 21.7/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.9,
      "資金流": 14,
      "市場環境": 12,
      "情緒分析": 6,
      "技術信號": 21.7,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 339.651585,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 4,
          "obvPoints": 0.8,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BDX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "優秀",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 17.52
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 732.47650135,
                "ma50": 725.4243990000001,
                "name": "QQQ",
                "close": 725.60999,
                "points": 1.4
              },
              "spy": {
                "ma20": 770.8954959000001,
                "ma50": 767.6259946999999,
                "name": "SPY",
                "close": 772.31,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.0031256405001026,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143135907,
                "url": "https://finnhub.io/api/news?id=27c02890af24c889c0aab6c83d79167c3a827dcdf275fdfee499eaf49e1d679b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson has delivered a strong share price run over the past year, which puts fresh focus on whether the current US$200.42 level is grounded in the cash it can generate. For anyone looking at the stock today, the central issue is how that recent performance lines up with the cash flow profile implied by its existing business. The share price return of 40.1% over the past year puts real pressure on the question of whether the valuation still lines up with the cash the business can...",
                "category": "company",
                "datetime": 1792768706,
                "headline": "Becton Dickinson (BDX) Stock Trades Below Fair Value After A 40% Run"
              },
              {
                "id": 143117659,
                "url": "https://finnhub.io/api/news?id=d3d5da0560620a3f74c361ce51da673588fcab24f982b19a88bb637fea1be7ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) heads into its fourth quarter fiscal 2026 report with investors focused on recent execution improvements, progress in higher growth businesses, fresh product launches, and a major U.S. manufacturing agreement. Becton Dickinson’s recent news arrives after a strong run in the market, with the share price up 28.18% over the past 90 days and a 1-year total shareholder return of 40.14%. This points to building momentum as investors reassess its execution, pipeline progress,...",
                "category": "company",
                "datetime": 1792735704,
                "headline": "Is Becton Dickinson (BDX) Fully Priced As Execution Improves Before Earnings?"
              },
              {
                "id": 143103803,
                "url": "https://finnhub.io/api/news?id=64e91c8c6fe34a2c1b6d7ffac246833155002d30dbbbee5bbf17bcba5d08f536",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.",
                "category": "company",
                "datetime": 1792689660,
                "headline": "BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?"
              },
              {
                "id": 142853630,
                "url": "https://finnhub.io/api/news?id=4b2beba5995983aab51cc36341a7167d0223e1ef8784b54bd734f557c1db5c81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A medical device maker selling more and earning a third less has […]",
                "category": "company",
                "datetime": 1791919780,
                "headline": "Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further?"
              },
              {
                "id": 142765452,
                "url": "https://finnhub.io/api/news?id=a2d04249e0cfb03122812ff45d246ca95db70a23c5a4af99161ab54176ce3cf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791558603,
                "headline": "Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142739135,
                "url": "https://finnhub.io/api/news?id=2b05c180fd0a81a8369f996c181556de6e23cca40b3dd270e5f8d59a11a60c21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease. Recent clinical progress comes on top of a busy October for Becton Dickinson, including a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the...",
                "category": "company",
                "datetime": 1791508638,
                "headline": "Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?"
              },
              {
                "id": 142733283,
                "url": "https://finnhub.io/api/news?id=300d330d82fff79b058e4dfb6b0419262ca0ee656d66e0fde7aa67a29a644970",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) recently announced a landmark partnership with the U.S. government to expand domestic manufacturing of essential medical consumables, including a planned US$19.00 billion multi-year investment and a goal to produce all U.S. needles domestically using American-made steel while receiving relief from certain future Section 232 tariffs. This move materially deepens BD’s role in U.S. healthcare infrastructure by tying long-term capital deployment directly to...",
                "category": "company",
                "datetime": 1791490220,
                "headline": "Will BD’s US$19 Billion U.S. Manufacturing Push and Tariff Relief Change Becton Dickinson's (BDX) Narrative"
              },
              {
                "id": 142697379,
                "url": "https://finnhub.io/api/news?id=266263d4bfc20da1cb9955c2d0af33b34d4339b28101d2e24e48433fa6b87667",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.",
                "category": "company",
                "datetime": 1791384900,
                "headline": "BDX Expands U.S. Manufacturing With $19B Healthcare Investment"
              }
            ],
            "raw_source": [
              {
                "id": 143262253,
                "url": "https://finnhub.io/api/news?id=8d25fea46ee0cc3112adfd0ee5609a5a12e264f0889547fba2b572dfeab8e188",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.",
                "category": "company",
                "datetime": 1793206260,
                "headline": "Waters Gears Up to Report Q3 Results: How to Play the Stock?"
              },
              {
                "id": 143259412,
                "url": "https://finnhub.io/api/news?id=f40b6a00bf5b9701ec2d281889ff682294d7617decd67808590eb5de919b05fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.",
                "category": "company",
                "datetime": 1793194200,
                "headline": "NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?"
              },
              {
                "id": 143254899,
                "url": "https://finnhub.io/api/news?id=152b1f73940080ef9a59aa2a20028af13222f64688822d8c6e1899271546a609",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. commercial launch of the BD® Liverty™ TIPS Stent Graft, advancing portal hypertension care by giving physicians greater flexibility to tailor treatment to each patient's hemodynamic needs. The next generation transjugular intrahepatic portosystemic shunt (TIPS) system is designed to provide physicians with deployment accuracy and control, and the flexibility to tailor treatment b",
                "category": "company",
                "datetime": 1793184600,
                "headline": "BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options"
              },
              {
                "id": 143253886,
                "url": "https://finnhub.io/api/news?id=8c506f142827413517793b5d9288fafbd93794ba63ed85354277d1a543a8f35b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1793179482,
                "headline": "What Did Halozyme Stock Investors Miss Before The Run?"
              },
              {
                "id": 143252944,
                "url": "https://finnhub.io/api/news?id=103b88ec663525608967ecdb02b9ba26187cdafc44b884b4425a9ae68666530a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148852132/image_2148852132.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Global Fund A Shares (without sales charge) posted a return of 2.10% in third quarter 2026. Read more here.",
                "category": "company",
                "datetime": 1793153400,
                "headline": "First Eagle Global Fund Q3 202 Portfolio Update"
              },
              {
                "id": 143238538,
                "url": "https://finnhub.io/api/news?id=750d30d484ade3a1e8159854b38c44d28a178a1afa8577adc1f3962168ef30fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.",
                "category": "company",
                "datetime": 1793114040,
                "headline": "ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus"
              },
              {
                "id": 143202807,
                "url": "https://finnhub.io/api/news?id=7d660da91e5e36c50c0862709fd06d2cc285ddbc13c635d959bafa56d1e4869b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.",
                "category": "company",
                "datetime": 1793033940,
                "headline": "DexCom Gears Up to Report Q3 Results: How to Play the Stock?"
              },
              {
                "id": 143200557,
                "url": "https://finnhub.io/api/news?id=d0d6070828cacd9dce680ca92936ee51472dc89887d81dfe1b2914264de18274",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BAX's Q3 revenues may rise, but earnings may fall amid tariffs, manufacturing costs and infusion pump challenges. Will stronger demand offset pressures?",
                "category": "company",
                "datetime": 1793024580,
                "headline": "Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?"
              },
              {
                "id": 143202806,
                "url": "https://finnhub.io/api/news?id=a74ffebdd34e717dd0a1baffb58ba857069c80f77c644922eefdd96523e240bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company will release its fourth-quarter earnings next week, and analysts anticipate a single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1793020468,
                "headline": "Becton, Dickinson and Company's Q4 2026 Earnings: What to Expect"
              },
              {
                "id": 143201015,
                "url": "https://finnhub.io/api/news?id=57e35b2bd284eb30a47293b8018e99be671d9e323f6d25cb064a537adbbe968a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268513467/image_2268513467.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "The First Eagle U.S. Fund reported a 4.36% return for Q3 2026, outperforming the S&P 500. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1793017800,
                "headline": "First Eagle U.S. Value Fund Q3 2026 Portfolio Review"
              },
              {
                "id": 143189783,
                "url": "https://finnhub.io/api/news?id=7941716229a8bbda4cc9791132af8c7c215310c0cbed87d7bde84e65b1623296",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253044633/image_2253044633.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Check out the October best dividend kings here.",
                "category": "company",
                "datetime": 1792983319,
                "headline": "Best Dividend Kings: October 2026"
              },
              {
                "id": 143136453,
                "url": "https://finnhub.io/api/news?id=e81e3df5b43e41dbcdaa003aebfa3683ba463d3d69c6489531ecdb7dd8d0b335",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson has seen stronger performance in its high growth segments, supported by ongoing product development, clinical trial progress, and a major U.S. manufacturing agreement that was announced before the scheduled fiscal 2026 fourth quarter earnings release on 5 November. The combination of a new domestic manufacturing deal and clinical milestones reinforces Becton Dickinson’s push toward higher value medtech platforms with recurring demand exposure. We will now look at how Becton...",
                "category": "company",
                "datetime": 1792771655,
                "headline": "What Becton Dickinson Stock's New U.S. Manufacturing Deal Means For Shareholders"
              },
              {
                "id": 143135907,
                "url": "https://finnhub.io/api/news?id=27c02890af24c889c0aab6c83d79167c3a827dcdf275fdfee499eaf49e1d679b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson has delivered a strong share price run over the past year, which puts fresh focus on whether the current US$200.42 level is grounded in the cash it can generate. For anyone looking at the stock today, the central issue is how that recent performance lines up with the cash flow profile implied by its existing business. The share price return of 40.1% over the past year puts real pressure on the question of whether the valuation still lines up with the cash the business can...",
                "category": "company",
                "datetime": 1792768706,
                "headline": "Becton Dickinson (BDX) Stock Trades Below Fair Value After A 40% Run"
              },
              {
                "id": 143133767,
                "url": "https://finnhub.io/api/news?id=32f6b2e8673e47899d273a67b23a2144259be1a6fb9adac7f2491f6314a01888",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "RMD heads into Q1 fiscal 2027 earnings with sleep device demand and new product launches supporting growth, while MatrixCare's divestiture weighs on revenues.",
                "category": "company",
                "datetime": 1792756500,
                "headline": "ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?"
              },
              {
                "id": 143117659,
                "url": "https://finnhub.io/api/news?id=d3d5da0560620a3f74c361ce51da673588fcab24f982b19a88bb637fea1be7ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) heads into its fourth quarter fiscal 2026 report with investors focused on recent execution improvements, progress in higher growth businesses, fresh product launches, and a major U.S. manufacturing agreement. Becton Dickinson’s recent news arrives after a strong run in the market, with the share price up 28.18% over the past 90 days and a 1-year total shareholder return of 40.14%. This points to building momentum as investors reassess its execution, pipeline progress,...",
                "category": "company",
                "datetime": 1792735704,
                "headline": "Is Becton Dickinson (BDX) Fully Priced As Execution Improves Before Earnings?"
              },
              {
                "id": 143103803,
                "url": "https://finnhub.io/api/news?id=64e91c8c6fe34a2c1b6d7ffac246833155002d30dbbbee5bbf17bcba5d08f536",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.",
                "category": "company",
                "datetime": 1792689660,
                "headline": "BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?"
              },
              {
                "id": 143098604,
                "url": "https://finnhub.io/api/news?id=483a5ac1a6d1017d1cd471e104d161ec1269851f07ea46c502c297327a06448d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792669556,
                "headline": "Can Boston Scientific Stock Jump 30%?"
              },
              {
                "id": 143100619,
                "url": "https://finnhub.io/api/news?id=5ed05253eec32aec0ac36c4336ca838cd46c85ff897c028216cb57ab1e78e489",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Illumina's Q3 results may benefit from strong clinical demand, NovaSeq X adoption, instrument placements and innovations despite persistent weakness in research markets.",
                "category": "company",
                "datetime": 1792669500,
                "headline": "ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance"
              },
              {
                "id": 143077026,
                "url": "https://finnhub.io/api/news?id=8f8a087b9a7e3a200ab1b84b9cf25e415216ea987778c64f3c5bfa27f092e2fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792632588,
                "headline": "Can Boston Scientific Stock Bounce Off This Support Again?"
              },
              {
                "id": 143069902,
                "url": "https://finnhub.io/api/news?id=76609308cca98e5095bb1be13805a13eb1102b42fe134ba83e8cd3213a109974",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Slatestone Wealth Partner & Chief Market Strategist Kenny Polcari talks about the biggest stories to start your trading day. Earnings are coming and causing stocks to rebound. SpaceX (SPCX) is topping its Q3 estimates, investors are watching health care earnings like Elevance Health (ELV), and what to expect with Meta's earnings coming later today. Kenny Polcari then sits down with Futurum CEO Daniel Newman to discuss Amazon (AMZN), Alphabet (GOOGL) (GOOG), and Microsoft (MSFT), the uncertainty in the tech trade, and how companies are monetizing AI.",
                "category": "company",
                "datetime": 1792591572,
                "headline": "SpaceX earnings roundup, Meta earnings preview, and tech trade fears"
              },
              {
                "id": 143070129,
                "url": "https://finnhub.io/api/news?id=b8196d22cbcb3f2058224d0aff561521f0e4da7f29889e1d354db6667be3a379",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.",
                "category": "company",
                "datetime": 1792590300,
                "headline": "DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line"
              },
              {
                "id": 143067801,
                "url": "https://finnhub.io/api/news?id=5c53b2916e431e5fa66c05efc1be494194c5a3ba0eef87a9b5194976543a0ca5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Boston Scientific's Q3 results hinge on MedSurg strength in Endoscopy and Neuromodulation, as Cardiovascular faces competitive pressures and softer sales.",
                "category": "company",
                "datetime": 1792585560,
                "headline": "BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?"
              },
              {
                "id": 143067778,
                "url": "https://finnhub.io/api/news?id=ebe0cb44f595c54c87e026cbb2cdb728d01f270e97c1f7cb2dbe1f915866b002",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "ECL gears up for Q3 earnings with strong growth prospects in AI infrastructure, Life Sciences and pricing, but rising costs could pressure margins.",
                "category": "company",
                "datetime": 1792584420,
                "headline": "Ecolab Gears Up to Report Q3 Results: How to Play the Stock?"
              },
              {
                "id": 143033042,
                "url": "https://finnhub.io/api/news?id=6120b1166a02a6998e562f4c1221ef443de13ebd507ed850b26fea70024aa16d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Investors hold Becton Dickinson (BDX) and Boston Scientific (BSX) for newer products that grow faster than the rest of their sales. Becton Dickinson sells everyday hospital supplies such as syringes, with faster-growing lines that include PureWick and biologic drug delivery. Boston Scientific sells cardiology devices such as WATCHMAN. Boston Scientific stock trades at 18.0 times earnings, compared with 55.7 for Becton Dickinson. You gain from that lower price only if the slowdown in WATCHMAN end",
                "category": "company",
                "datetime": 1792537526,
                "headline": "Should Becton Dickinson Stock Holders Look At Boston Scientific Instead?"
              },
              {
                "id": 143008352,
                "url": "https://finnhub.io/api/news?id=47fffa69c70cc725d1883a4bc429f903081db397e168351766bac723d6ea7cf7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323538000/image_1323538000.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company stock surged 26% in 4 months as fundamentals rebounded; now near fair value at 15x P/E, rated HOLD. Click for more on BDX stock.",
                "category": "company",
                "datetime": 1792410311,
                "headline": "Becton, Dickinson: Fundamentals Remain Solid, Trades Near Fair Value (Rating Downgrade)"
              },
              {
                "id": 142921392,
                "url": "https://finnhub.io/api/news?id=2c78bcaaa7a43c6a46f54c48bf514d18ebf0401dc2599a79c95b2a6dd89ac00c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Investors in Boston Scientific (BSX) hold stakes in a medical device maker that grew revenue 13.5% over the twelve months to June 2026. Yet the shares have lost 54.7% over the past year, trailing a 17.3% gain for the S&P 500. In August, a cyberattack disrupted the company's manufacturing and order shipments. So has the risk in holding Boston Scientific shares gone up or down over the past year.",
                "category": "company",
                "datetime": 1792091887,
                "headline": "Is Boston Scientific Stock Riskier Than It Was A Year Ago?"
              },
              {
                "id": 142920605,
                "url": "https://finnhub.io/api/news?id=764a31f46f7fea72f54cb721779f0918639cf5d6a2db1a3c2d2c0fb4b86f420d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.",
                "category": "company",
                "datetime": 1792081320,
                "headline": "BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients"
              },
              {
                "id": 142919355,
                "url": "https://finnhub.io/api/news?id=e4655fb317207630c952dab7a0df29adff8854bb4a3f7189028bf4e6f83c0ba5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics. Three healthcare stocks prove that the most reliable paycheck in a portfolio is often the one nobody talks about.",
                "category": "company",
                "datetime": 1792079158,
                "headline": "3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades"
              },
              {
                "id": 142888398,
                "url": "https://finnhub.io/api/news?id=ef7c7029bef1f6c640c65a25788aafde6dcff4633ad4476372e4ff68562445ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends, excluding readings above a hundred. Investors evaluating the stock must look ahead to model potential returns. So what might a share bought at $43.31 be worth three years from now.",
                "category": "company",
                "datetime": 1792011329,
                "headline": "What Could BSX Stock Be Worth In Three Years?"
              },
              {
                "id": 142883035,
                "url": "https://finnhub.io/api/news?id=a1d80f5cc8811919bd450bf816908b7eeab590f19e2606f5e608e661114006ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) has steady demand for its medical devices, together with a long history of paying dividends. The company’s product range includes medical essentials, connected care, biopharma systems, and devices for interventional procedures, which means it is exposed to spending on essential healthcare. Its decision to separate the Biosciences and Diagnostic Solutions […]",
                "category": "company",
                "datetime": 1791984564,
                "headline": "Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look?"
              },
              {
                "id": 142853630,
                "url": "https://finnhub.io/api/news?id=4b2beba5995983aab51cc36341a7167d0223e1ef8784b54bd734f557c1db5c81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A medical device maker selling more and earning a third less has […]",
                "category": "company",
                "datetime": 1791919780,
                "headline": "Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further?"
              },
              {
                "id": 142765452,
                "url": "https://finnhub.io/api/news?id=a2d04249e0cfb03122812ff45d246ca95db70a23c5a4af99161ab54176ce3cf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791558603,
                "headline": "Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142739135,
                "url": "https://finnhub.io/api/news?id=2b05c180fd0a81a8369f996c181556de6e23cca40b3dd270e5f8d59a11a60c21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease. Recent clinical progress comes on top of a busy October for Becton Dickinson, including a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the...",
                "category": "company",
                "datetime": 1791508638,
                "headline": "Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?"
              },
              {
                "id": 142733283,
                "url": "https://finnhub.io/api/news?id=300d330d82fff79b058e4dfb6b0419262ca0ee656d66e0fde7aa67a29a644970",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) recently announced a landmark partnership with the U.S. government to expand domestic manufacturing of essential medical consumables, including a planned US$19.00 billion multi-year investment and a goal to produce all U.S. needles domestically using American-made steel while receiving relief from certain future Section 232 tariffs. This move materially deepens BD’s role in U.S. healthcare infrastructure by tying long-term capital deployment directly to...",
                "category": "company",
                "datetime": 1791490220,
                "headline": "Will BD’s US$19 Billion U.S. Manufacturing Push and Tariff Relief Change Becton Dickinson's (BDX) Narrative"
              },
              {
                "id": 142726188,
                "url": "https://finnhub.io/api/news?id=6045ab225b019d87298666ec18c222942e3ff7f5b516c138ea8f34a75f3efa8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, the Global Surgery Foundation (GSF) and the Business Council for International Understanding (BCIU) brought together healthcare, government, academia, and industry leaders to advance solutions aimed at reducing maternal mortality worldwide. On the sidelines of the 81st United Nations General Assembly (UNGA), participants explored how continuous noninvasive blood pressure monitoring and advanced hemodynam",
                "category": "company",
                "datetime": 1791456600,
                "headline": "BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide"
              },
              {
                "id": 142830610,
                "url": "https://finnhub.io/api/news?id=3b3de4189618d0775e53bca1464b601904e8132d06e731efde271907baef0aa3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The trial's iliac arm enrolled 120 patients across 28 investigative sites located in Australia, Europe, New Zealand, and the US.",
                "category": "company",
                "datetime": 1791449442,
                "headline": "BD reports nine-month AGILITY trial data for Revello stent"
              },
              {
                "id": 142728619,
                "url": "https://finnhub.io/api/news?id=b99dd923bdacf8c6dd0a84e684643c52ee4d379422d4c9927954f8c7ed7db45f",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Barclays  analyst Christopher Pasquale   initiates coverage on Becton Dickinson (NYSE:BDX) with a Underweight rating and announces Price Target of $165.",
                "category": "company",
                "datetime": 1791384908,
                "headline": "Barclays Initiates Coverage On Becton Dickinson with Underweight Rating, Announces Price Target of $165"
              },
              {
                "id": 142697379,
                "url": "https://finnhub.io/api/news?id=266263d4bfc20da1cb9955c2d0af33b34d4339b28101d2e24e48433fa6b87667",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.",
                "category": "company",
                "datetime": 1791384900,
                "headline": "BDX Expands U.S. Manufacturing With $19B Healthcare Investment"
              },
              {
                "id": 140420211,
                "url": "https://finnhub.io/api/news?id=c9045c53ac19ad80d94a07c2e8320fa134ac76c18ad5824d79898864952688d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Intel downgraded, Marvell upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1791381613,
                "headline": "Intel downgraded, Marvell upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 142695109,
                "url": "https://finnhub.io/api/news?id=7ceee4fdbf48bfbdadadb7e47a6b191621b7505f64e7b449c1547fbc7ac1821d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease",
                "category": "company",
                "datetime": 1791374400,
                "headline": "BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results"
              },
              {
                "id": 142666979,
                "url": "https://finnhub.io/api/news?id=fc6a93f1c70c88c8ccc8cb4ac14022994179855389cbf97e26ce218a6c1442ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX), a global medical technology firm and the largest domestic producer of critical medical consumables, on Tuesday announced a monumental partnership with the U.S. government. The agreement aims to drastically expand domestic manufacturing and fortify the supply chain for vital medical products that patients and clinicians rely on daily. Massive Investment in Domestic Production The strategic alliance directly supports the Trump administration’s ongoing init",
                "category": "company",
                "datetime": 1791304253,
                "headline": "Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing"
              },
              {
                "id": 142663320,
                "url": "https://finnhub.io/api/news?id=290c2852e687f8295a8b270b7a62084e2631bd80d0ff744d5ca52d5f6f0d5148",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn., the birthplace of the world's first fully sterile, single-use disposable plastic syringe and the largest syringe manufacturing operation in the United States.",
                "category": "company",
                "datetime": 1791291600,
                "headline": "BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan"
              },
              {
                "id": 142662851,
                "url": "https://finnhub.io/api/news?id=b68a6d632dba45b4a833404704eb36ff38ef23b56e99d5456dc2617b550cd9d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The move makes the needle- and medical-device maker the latest company to pledge to expand domestic manufacturing to secure an exemption from the Trump administration’s tariffs.",
                "category": "company",
                "datetime": 1791290100,
                "headline": "Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief"
              },
              {
                "id": 142662138,
                "url": "https://finnhub.io/api/news?id=93e2210542fbb465d488ad34188d4a0fcd29f6063acdaadcf71c15bc5e5ee9e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worldwide president of the Surgery business unit at BD, effective immediately.",
                "category": "company",
                "datetime": 1791283800,
                "headline": "BD Appoints Ferass Abuzaina as Worldwide President of Surgery"
              },
              {
                "id": 142662137,
                "url": "https://finnhub.io/api/news?id=cc8a49e22d3e213f7cbcf25b0334fb96fe1368df0b6daea37d9c95ad5499bf7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world's leading medical technology companies and the nation's largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day.",
                "category": "company",
                "datetime": 1791282900,
                "headline": "BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience"
              },
              {
                "id": 142665101,
                "url": "https://finnhub.io/api/news?id=c60f1aadc08fd9c2e4b189e8b268af150aa562e53e40b17b9cf2ae43d53cb785",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/06/President-Donald-Trump-Thanks-The-Crowd-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Trump says Becton Dickinson will invest $3 Billion in U.S. medical manufacturing as medical-device tariffs are set for year-end.",
                "category": "company",
                "datetime": 1791264369,
                "headline": "Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End"
              },
              {
                "id": 142648516,
                "url": "https://finnhub.io/api/news?id=2aa46d6475b0014461cec1c3503045c642289d545eb8a2f23d4e9d96e2656f65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Investing.com -- Becton Dickinson and Co (NYSE:BDX) has agreed to invest $3 billion to expand U.S. manufacturing of essential medical products, President Donald Trump said on Tuesday, as his administration pushes companies to bring more healthcare production onshore.",
                "category": "company",
                "datetime": 1791262322,
                "headline": "Trump says Becton Dickinson to invest $3 billion in US medical manufacturing"
              },
              {
                "id": 142664337,
                "url": "https://finnhub.io/api/news?id=246d865b1f4f6b7b478c8d10c742ea1796cc46b066136dace374fb95b72764fb",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "https://truthsocial.com/@realDonaldTrump/posts/117391801119298224 ",
                "category": "company",
                "datetime": 1791251305,
                "headline": "President Trump Posts On Truth Social \"HUGE INVESTMENT WIN for NEBRASKA AND THE U.S.! Beckton Dickenson (BD), one of the largest Medical Device Manufacturers, has agreed to an Investment of 3 BILLION DOLLARS to Onshore Manufacturing of Essential Medical Products (syringes, needles, lab kits, and more) that American Patients and Hospitals depend on...The reason for BD’s announcement is my strong Medical Device TARIFFS, which will be in place by the end of the year...\""
              },
              {
                "id": 142635944,
                "url": "https://finnhub.io/api/news?id=dc066b8c6a3a9aeb3d6c7107e735df54e167a5548fdc5ddd08cb2b5c75575346",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Becton Dickinson (NYSE:BDX) held its third-quarter earnings conference call on Thursday. Below is the complete transcript from the call.\nThis content is powered by Benzinga APIs. For comprehensive financial data and",
                "category": "company",
                "datetime": 1791182118,
                "headline": "Becton Dickinson Q3 2026 Earnings Call: Complete Transcript"
              },
              {
                "id": 142588574,
                "url": "https://finnhub.io/api/news?id=84ccaec2825b0d28abb6caaf6d3fe52e576a7aa1808c568dab8b141291eaad47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Medical-dental supplies see durable demand from specialty care, AI and aging trends, with McKesson and peers navigating tariffs and inflation.",
                "category": "company",
                "datetime": 1790944860,
                "headline": "Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex"
              },
              {
                "id": 142588475,
                "url": "https://finnhub.io/api/news?id=6fd48e7304687ae83dfa7d4a7e88d779d862b62a79e75022612c93c7e216a109",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.",
                "category": "company",
                "datetime": 1790943000,
                "headline": "QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel"
              },
              {
                "id": 142557889,
                "url": "https://finnhub.io/api/news?id=6aef2f6be077d7cadc16d7f461abb00cb9e3ac60b722a6e258a13f9e2397edee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.",
                "category": "company",
                "datetime": 1790855760,
                "headline": "5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve"
              },
              {
                "id": 142495990,
                "url": "https://finnhub.io/api/news?id=fd783d9531d6aea985a3f147cf94ae80e7fc927a2199f6843cae0a0b5759d2b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.",
                "category": "company",
                "datetime": 1790688410,
                "headline": "3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth"
              },
              {
                "id": 142496159,
                "url": "https://finnhub.io/api/news?id=83f71601a00f54a74e6598b61c5d123e4058c47aabeb722ac13ef83ef9197025",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 70 years of manufacturing in Sandy, Utah, a key part of the company's U.S. manufacturing network and a critical source of the medical technologies healthcare providers and patients depend on for daily care worldwide.",
                "category": "company",
                "datetime": 1790686800,
                "headline": "BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy"
              },
              {
                "id": 142470210,
                "url": "https://finnhub.io/api/news?id=1eb8fcec8e4958ff4b4fc4f435a8735d9886aafb4da564a75f8426e062cd604b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.",
                "category": "company",
                "datetime": 1790622564,
                "headline": "How Big Could BSX Stock's Next Fall Be?"
              },
              {
                "id": 142469358,
                "url": "https://finnhub.io/api/news?id=df6606a47f06bf41c262e3c74d80e5e1a9270c0e6b943a74aeee5a7d769eac3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.",
                "category": "company",
                "datetime": 1790608500,
                "headline": "Here's Why You Should Retain BDX Stock in Your Portfolio for Now"
              },
              {
                "id": 142453159,
                "url": "https://finnhub.io/api/news?id=a858de7c4755f727def1d938c4a395431e61d53c9193adecc8cfe68e25951e21",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats list here.",
                "category": "company",
                "datetime": 1790556963,
                "headline": "Best Dividend Aristocrats For October 2026"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 57,
            "discarded_article_count": 48
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.7,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1672160,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1389080,
              "avg_vol_20": 1496995,
              "avg_vol_30": 1672160,
              "range_pct_10": 0.07393936769829877,
              "range_pct_20": 0.12687020905923338,
              "range_pct_30": 0.12687020905923338,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8307099799062291,
              "dist_to_20d_high": 0.026487753778620254,
              "down_shrink_days": 5,
              "breakout_level_20d": 200.47,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5827953484633878
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.0031256405001026,
              "turnoverUsdM": 339.651585,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.BDX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 187.3414,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.8,
            "stop_loss_percent": 4,
            "take_profit_price": 209.2074,
            "target_multiplier": 2.2,
            "technical_strength": 2.45,
            "take_profit_percent": 7.2
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.7971913130227917,
          "stopLossPercent": 4.006251281000205,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 3.9093,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 72.87
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2431
    },
    "kdj": {
      "d": 75.51,
      "j": 45.46,
      "k": 65.49,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 79.29
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -3791025,
      "recentSlope": -145052.5,
      "previousSlope": 259610
    },
    "rsi": 69.23,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 191.2111,
      "position": "SAR喺價下",
      "distancePct": 2.02,
      "previousTrend": "上升"
    },
    "ma50": 186.178,
    "macd": {
      "macd": 3.8622585883959175,
      "trend": "強烈看漲",
      "signal": 3.2551958713804647,
      "histogram": 0.6070627170154528
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 188.0533,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 15
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.16,
      "score": 6,
      "avgVolume": 1494084,
      "currentVolume": 1740375
    },
    "derived": {
      "ma20": 188.8975,
      "ma50": 186.178,
      "prevClose": 195.03,
      "avgVolume10": 1398368,
      "avgVolume20": 1494084,
      "changePercent": 0.07,
      "avgVolumeForScore": 1494084
    },
    "ma_cross": {
      "ma20": 188.8975,
      "ma50": 186.178,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 188.0895,
      "prevMa50": 185.8902,
      "spreadPct": 1.46,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 174.7344,
      "upper": 203.0606,
      "position": "上半部"
    },
    "rsi_short": 55.6,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.16
    }
  }
}

{
  "close": 195.16,
  "volume": 1740375,
  "changePercent": 0.07
}